Brii Biosciences
Wednesday, June 05, 2024
Company Presentation
![Multiple Therapeutics](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/blank.png)
Company Presentation Theater 2
Brii Biosciences Limited (“Brii Bio”, stock code: 2137.HK) is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious and central nervous system diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B viral infection (HBV), postpartum depression (PPD), and major depressive disorder (MDD). The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit www.briibio.com.
![Brii Biosciences](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1812125-1-JPG.png)
Company Website:
https://www.briibio.com/en/
Lead Product in Development:
BRII-179, BRII-835, BRII-877
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5
Exchange
Hong Kong Exchange
Ticker
2137.HK
Company HQ City
San Mateo
Company HQ State
California
Company HQ Country
United States
CEO/Top Company Official
Zhi Hong, PhD
Development Phase of Primary Product
Phase II
Primary Speaker